**Background:** Frailty is a condition characterized by decline in function of multiple homeostatic systems, leading to increased vulnerability to stressors and adverse health outcomes. Older age is a major risk factor for severe COVID-19, potentially due to immunosenescence and chronic low-grade inflammation. This narrative review aims to summarize evidence on how COVID-19 infection and frailty interact etiopathogenetically, identifying mechanisms that promote functional decline in frail subjects.
**Methods:** This is a narrative review (not a systematic review despite the authors' stated aim) synthesizing published literature on COVID-19, frailty, sarcopenia, functional decline, cognitive decline, and vaccination response in older adults. The authors discuss mechanistic pathways including immunosenescence, cytokine storm, mitochondrial dysfunction, gut microbiota alterations, and neuroinflammation.
**Key Results:** The review reports that the majority of COVID-19 cases occurred in people aged 60 and over, with death rates increasing exponentially with age: 0.4% among those aged 40–49, 3.6% among those aged 60–69, and 14.8% among those aged >80. In Italy, 24% of patients with COVID-19 who died did not present with fever, 27% did not present with dyspnea, and 61% did not present with cough at onset. The review identifies that elevated concentrations of CRP, IL-6, and TNF-α are the indices most strongly correlating with sarcopenia and frailty. One study cited found that 87.4% of patients had at least one persistent post-COVID symptom, most commonly dyspnea or fatigue. Another study indicated post-infectious physical function and fitness may be impaired for up to two years after illness. Regarding vaccination, Salvagno et al. showed total anti-SARS-CoV-2 RBD antibodies were inversely associated with age after the first two vaccine doses, with male sex after the second dose, and in seronegative subjects at baseline. Another study highlighted that frailest patients show an overall reduced response to anti-SARS-CoV-2 vaccination compared to healthy individuals, with significantly greater decline in antibody titers within the first 6 months.
**Clinical Implications:** The review suggests that frailty assessment should be integrated into COVID-19 clinical management to identify patients requiring close monitoring and to distinguish those needing hospitalization from those suitable for home care. The authors emphasize that COVID-19 exploits pre-existing frailty through amplification of inflammation, cytokine production in the nervous system, and mitochondrial dysfunction, potentially accelerating aging processes. For post-COVID-19 patients, inflammation is implicated in sarcopenia progression, functional activity decline, and dementia. The review highlights that frail elderly patients may have reduced vaccine immunogenicity, particularly males and those of advanced age, suggesting continued risk of infection or recurrence despite vaccination. The authors call for primary and rehabilitative action plans to address sarcopenia, functional deterioration, cognitive decline, and depression in post-COVID patients.